A director at Dexcom Inc sold/sold after exercising options 4,137 shares at 140.000USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription. There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and who can benefit from continuous glucose monitoring (CGM) technology. Today, Dexcom G7 is available for them with a prescription. Stelo, cleared for use without a prescription, will make it even easier for this population to access lead...
EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom continuous glucose monitoring (CGM) for automated insulin delivery (AID) systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and d...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th. The live presentation is scheduled to begin at approximately 8:40 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through ...
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported basis. International revenue growth was 23% on an organic1 basis. GAAP operating income of $216.9 million or 21.0% of revenue, an increase of 560 basis points compared to the fourth quarter o...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (888) 41...
GALWAY, Ireland--(BUSINESS WIRE)-- (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, has officially broken ground on its new state-of-the-art manufacturing facility, located in Athenry, Co. Galway. This marks the first step in the realisation of this facility, which will bring more than 1,000 jobs to the area and represents one of the biggest single private sector investments ever in the West of Ireland. Dexcom’s first manufacturing facility in Europe will ensure the flow of products throughout EMEA, with the potential to lower the ...
EDINBURGH, Scotland--(BUSINESS WIRE)-- (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The announcement comes just a month after the system launched in the United States and combines the power and accuracy of Dexcom G7 with the discretion of the Tandem t:slim X2. “For over a decade Dexcom has been pioneering industry leading CGM connectivity, meaning ...
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022. U.S. revenue is expected to be approximately $765 million, representing growth of 26% over the fourth quarter of 2022. International revenue is expected to be approximately $265 million, an increase of 27% over the fourth quarter of 2022. For fiscal 2023, total preliminary, unaudited revenue is e...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024. The live presentation is scheduled to begin at approximately 12:45 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through innovative continuous...
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, the Dexcom G7 Continuous Glucose Monitoring (CGM) System with the t:slim X2™ insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM, the world’s most accurate1,2 CGM system. This press release features multimedia. View the full release here: Dexcom G7 CGM now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in the U.S. (Photo: Business Wire) “There’s a reason Dexcom is the undisputed...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29th. The live presentation is scheduled to begin at approximately 8:30 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through inn...
SAN DIEGO et ÉDIMBOURG, Écosse--(BUSINESS WIRE)-- (NASDAQ : DXCM), le chef de file mondial des systèmes de surveillance continue du glucose (CGM) en temps réel pour les personnes atteintes de diabète, fait équipe avec à l'échelle mondiale pour aider à sensibiliser à la nécessité d’améliorer l’accès aux technologies qui changent la vie en matière de gestion du diabète durant le Mois national de sensibilisation au diabète aux États-Unis et au Canada (novembre) et à l’occasion de la Journée mondiale du diabète (14 novembre). Ce communiqué de presse contient des éléments multimédias. Voir le co...
SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)-- (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) systems for people with diabetes, is teaming up with from around the globe to help raise awareness for the need to improve access to life-changing diabetes technology during National Diabetes Awareness Month in the U.S. and Canada (November) and on World Diabetes Day (November 14). This press release features multimedia. View the full release here: Dexcom Warriors from top left to right: Bambi B., Enrrique A., Nenad Š., Qiana D. & Lily D., Nick J. Dexcom War...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to keep their glucose levels in range, and that almost half (45%) don’t understand what a Hybrid Closed Loop System (HCL) is or how HCL could benefit them1-2. Findings also showed that 99% of healthcare providers expect the NICE TA for HCL systems will somewhat or significantly help change the lives of people living with type 1 diabetes for the better1-2. Dexcom’s research fol...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $975.0 million on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 24% and international revenue growth of 33% on a reported basis. International revenue growth was 30% on an organic1 basis. GAAP operating income of $205.5 million or 21.1% of revenue, an increase of 190 basis points compared to the third quarter of 20...
BURNABY, Colombie-Britannique--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ : DXCM), un chef de file à l’échelle internationale dans le domaine de la surveillance continue du glucose en temps réel (SCGtr) pour les personnes atteintes de diabète, a annoncé aujourd’hui que la nouvelle génération du système de surveillance continue du glucose (SCG), le Dexcom G7, sera offerte aux Canadiennes et aux Canadiens âgés de 2 ans ou plus qui sont atteints de n’importe quel type de diabète, notamment le diabète gestationnel, à compter du 10 octobre 2023. Avec ce lancement, le système de SCG d’une exactitude iné...
BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant. Its introduction brings the most accurate CGM on the market*,1 to Canadians, offering users a new way to gain greater control of their diabetes. This press release features multimedia. View the ful...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), le leader mondial du suivi de la glycémie en continu et en temps réel pour les personnes diabétiques, a annoncé ce jour de nouveaux résultats d’études cliniques qui démontrent une nouvelle fois les avantages de l’utilisation de la SGC ; en outre Dexcom a donné plus de détails sur son portefeuille croissant d’offres automatisées d’administration d’insuline à l’occasion de la 59e réunion annuelle de l’Association européenne pour l’étude du diabète tenue du 2 au 6 octobre 2023 à Hambourg (Allemagne). Dexcom est le leader de la SGC en temps réel et le...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Association for the Study of Diabetes held Oct. 2-6, 2023 in Hamburg, Germany. The leader in real-time CGM and the clear choice for automated insulin delivery New results from the COMISAIR seven-year study, the longest prospective r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.